# Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

> **NCT06839053** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Mantle Cell Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Mantle Cell Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Gastrointestinal Endoscopy
- **BIOLOGICAL:** Rituximab
- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06839053
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2028-08-01
- **Final completion:** 2032-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839053, "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06839053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*